Detalles de la búsqueda
1.
Effect of preceding drug therapy on the renal and cardiovascular outcomes of combined sodium-glucose cotransporter-2 inhibitor and glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes and chronic kidney disease.
Diabetes Obes Metab
; 2024 May 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-38764356
2.
Correction to: Switching from Warfarin to rivaroxaban induces sufficiency of vitamin K and reduction of arterial stiffness in patients with atrial fibrillation.
Heart Vessels
; 35(12): 1734, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-32691115
3.
Switching from Warfarin to rivaroxaban induces sufficiency of vitamin K and reduction of arterial stiffness in patients with atrial fibrillation.
Heart Vessels
; 35(12): 1727-1733, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-32577819
4.
Renal effects of sodium glucose co-transporter 2 inhibitors in Japanese type 2 diabetes mellitus patients with home blood pressure monitoring.
Clin Exp Hypertens
; 41(7): 637-644, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30373408
5.
Pretreatment body mass index affects achievement of target blood pressure with sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease.
Hypertens Res
; 47(3): 628-638, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-37848562
6.
Influence of the combination of SGLT2 inhibitors and GLP-1 receptor agonists on eGFR decline in type 2 diabetes: post-hoc analysis of RECAP study.
Front Pharmacol
; 15: 1358573, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38601470
7.
Cross-sectional survey of hypertension management in clinical practice in Japan: the Kanagawa Hypertension Study 2021 conducted in collaboration with Japan Medical Association Database of Clinical Medicine.
Hypertens Res
; 46(11): 2447-2459, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37532949
8.
Renoprotective effects of combination treatment with sodium-glucose cotransporter inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus according to preceding medication.
Diab Vasc Dis Res
; 20(6): 14791641231222837, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38096503
9.
The concomitant use of sodium-glucose co-transporter 2 inhibitors improved the renal outcome of Japanese patients with type 2 diabetes treated with glucagon-like peptide 1 receptor agonists.
Cardiovasc Endocrinol Metab
; 12(4): e0292, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37779602
10.
Polypharmacy influences the renal composite outcome in patients treated with sodium-glucose cotransporter 2 inhibitors.
Clin Transl Sci
; 15(4): 1050-1062, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34989473
11.
Comparison of the blood pressure management between sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists.
Sci Rep
; 12(1): 16106, 2022 09 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-36167964
12.
Comparison of renal outcomes between sodium glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists.
Diabetes Res Clin Pract
; 185: 109231, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-35131376
13.
Sodium-glucose cotransporter 2 inhibitor-induced reduction in the mean arterial pressure improved renal composite outcomes in type 2 diabetes mellitus patients with chronic kidney disease: A propensity score-matched model analysis in Japan.
J Diabetes Investig
; 12(8): 1408-1416, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-33377605
14.
Comparison of questionnaire responses regarding awareness of Japanese Society of Hypertension guidelines for the management of hypertension between 2014 and 2019 in primary care.
Hypertens Res
; 44(9): 1147-1157, 2021 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-34253880
15.
Blood pressure after treatment with sodium-glucose cotransporter 2 inhibitors influences renal composite outcome: Analysis using propensity score-matched models.
J Diabetes Investig
; 12(1): 74-81, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-32506833
16.
Retrospective Analysis of the Renoprotective Effects of Long-Term Use of Six Types of Sodium-Glucose Cotransporter 2 Inhibitors in Japanese Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.
Diabetes Technol Ther
; 23(2): 110-119, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32721227
17.
The influence of long-term administration of SGLT2 inhibitors on blood pressure at the office and at home in patients with type 2 diabetes mellitus and chronic kidney disease.
J Clin Hypertens (Greenwich)
; 22(12): 2306-2314, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33086437
18.
Relation between Blood Pressure Management and Renal Effects of Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Patients with Chronic Kidney Disease.
J Diabetes Res
; 2019: 9415313, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31781668
19.
Retrospective analysis of effects of sodium-glucose co-transporter 2 inhibitor in Japanese type 2 diabetes mellitus patients with chronic kidney disease.
Diab Vasc Dis Res
; 16(1): 103-107, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30284913
20.
Effects of sodium-glucose cotransporter 2 inhibitors on urinary excretion of intact and total angiotensinogen in patients with type 2 diabetes.
J Investig Med
; 65(7): 1057-1061, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28596160
Resultados
1 -
20
de 20
1
Próxima >
>>